Chemical Works of Gedeon Richter Plc (RGEDF)
39.30
-0.84
(-2.08%)
USD |
OTCM |
Sep 15, 16:00
Chemical Works of Gedeon Richter Enterprise Value : 6.348B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 6.348B |
| September 14, 2026 | 6.501B |
| September 11, 2026 | 6.365B |
| September 10, 2026 | 6.653B |
| September 09, 2026 | 6.594B |
| September 08, 2026 | 6.596B |
| September 04, 2026 | 6.729B |
| September 03, 2026 | 6.516B |
| September 02, 2026 | 6.614B |
| September 01, 2026 | 6.875B |
| August 31, 2026 | 6.880B |
| August 28, 2026 | 7.071B |
| August 27, 2026 | 7.071B |
| August 26, 2026 | 7.108B |
| August 25, 2026 | 7.165B |
| August 24, 2026 | 7.083B |
| August 21, 2026 | 6.808B |
| August 20, 2026 | 6.808B |
| August 19, 2026 | 6.934B |
| August 18, 2026 | 6.791B |
| August 17, 2026 | 6.848B |
| August 14, 2026 | 6.951B |
| August 13, 2026 | 6.751B |
| August 12, 2026 | 6.855B |
| August 11, 2026 | 6.748B |
| Date | Value |
|---|---|
| August 10, 2026 | 6.500B |
| August 07, 2026 | 6.432B |
| August 06, 2026 | 6.113B |
| August 05, 2026 | 6.619B |
| August 04, 2026 | 6.173B |
| August 03, 2026 | 6.108B |
| July 31, 2026 | 6.094B |
| July 30, 2026 | 6.082B |
| July 29, 2026 | 5.945B |
| July 28, 2026 | 6.037B |
| July 27, 2026 | 5.936B |
| July 24, 2026 | 5.924B |
| July 23, 2026 | 5.925B |
| July 22, 2026 | 5.837B |
| July 21, 2026 | 6.165B |
| July 20, 2026 | 6.165B |
| July 17, 2026 | 6.214B |
| July 16, 2026 | 6.217B |
| July 15, 2026 | 6.103B |
| July 14, 2026 | 6.284B |
| July 13, 2026 | 6.109B |
| July 10, 2026 | 6.326B |
| July 09, 2026 | 6.105B |
| July 08, 2026 | 6.313B |
| July 07, 2026 | 6.313B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 528.30B |
| ANI Pharmaceuticals, Inc. | 1.891B |
| Corcept Therapeutics, Inc. | 11.66B |
| Veru, Inc. | 16.79M |
| Avadel Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 122.85M |
| Revenue (Quarterly) | 777.18M |
| Total Expenses (Quarterly) | 653.98M |
| EPS Diluted (Quarterly) | 0.6729 |
| Gross Profit Margin (Quarterly) | 70.03% |
| Profit Margin (Quarterly) | 15.81% |
| Earnings Yield | 9.16% |
| Operating Earnings Yield | 13.96% |
| Normalized Earnings Yield | 9.160 |